JP2007031291A - Body weight increase-inhibiting agent and body weight increase-inhibiting drink - Google Patents
Body weight increase-inhibiting agent and body weight increase-inhibiting drink Download PDFInfo
- Publication number
- JP2007031291A JP2007031291A JP2005212821A JP2005212821A JP2007031291A JP 2007031291 A JP2007031291 A JP 2007031291A JP 2005212821 A JP2005212821 A JP 2005212821A JP 2005212821 A JP2005212821 A JP 2005212821A JP 2007031291 A JP2007031291 A JP 2007031291A
- Authority
- JP
- Japan
- Prior art keywords
- butyric acid
- acid bacteria
- weight gain
- body weight
- inhibiting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Non-Alcoholic Beverages (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
本発明は、体重増加を抑制する効果に優れていて、かつ副作用の恐れがなく、安全性に優れた体重増加抑制剤及び体重増加抑制飲料に関する。 The present invention relates to a weight gain inhibitor and a weight gain inhibitor beverage that are excellent in the effect of suppressing weight gain, have no fear of side effects, and are excellent in safety.
現代社会の高カロリー型食生活のもたらす問題の一つに、カロリー過剰摂取に基づく体重の増加、いわゆる肥満が挙げられる。体重の増加により肥満に至ると、美容上望ましくないというだけでなく、糖尿病、高血圧症及び高脂血症などの生活習慣病の発生を導く大きな健康リスクとなる。また、糖尿病、高血圧症及び高脂血症などの生活習慣病を患っている患者の体重増加は、かかる疾病の悪化を誘導する場合もある。このように生活習慣病と体重増加は密接な関係があり、体重増加を抑制することは生活習慣病の発生を抑える上でも重要であると考えられている。 One of the problems caused by high-calorie diets in modern society is an increase in body weight due to excessive intake of calories, so-called obesity. Obesity resulting from an increase in body weight is not only cosmetically undesirable, but also represents a major health risk that leads to the development of lifestyle-related diseases such as diabetes, hypertension and hyperlipidemia. In addition, weight gain in patients suffering from lifestyle-related diseases such as diabetes, hypertension and hyperlipidemia may induce exacerbation of such diseases. As described above, lifestyle-related diseases and weight gain are closely related, and it is considered that suppressing weight gain is important for suppressing the occurrence of lifestyle-related diseases.
体重の増加を抑制するためには、十分な運動や偏りのない食生活が重要である。しかし、食事療法は、カロリー計算が繁雑であり、また管理の困難さから必ずしも良好な効果を得難い。一方、運動による体重増加の抑制は、十分な効果が得られない場合がある。また、体重増加は必ずしも運動不足や食生活といった環境因子を原因とするわけではなく、遺伝因子を原因とする場合もあると考えられている。したがって、運動や偏りのない食生活だけでは十分に対応ができず、体重増加抑制の作用がある薬が開発されている。 In order to suppress the increase in weight, it is important to have sufficient exercise and a balanced diet. However, dietary therapy is complicated to calculate calories, and it is difficult to obtain a good effect due to the difficulty of management. On the other hand, suppression of weight gain due to exercise may not provide a sufficient effect. In addition, weight gain is not necessarily caused by environmental factors such as lack of exercise or eating habits, but may be caused by genetic factors. Therefore, drugs that have an action of suppressing weight gain have been developed, which cannot be adequately dealt with only by diet and exercise without bias.
特許文献１には、アンギオテンシンII拮抗作用を有する化合物、そのプロドラッグまたはその塩を含有してなる体重増加の抑制剤が開示されている。 Patent Document 1 discloses a body weight gain inhibitor comprising a compound having an angiotensin II antagonistic activity, a prodrug thereof, or a salt thereof.
特許文献２には、特定のアミノ酸配列（２３個アミノ酸）を含有するポリペプチド、そのアミド又はエステル又はその塩を含有してなる体重増加抑制剤 、体重減少剤、脂肪量増加剤、摂食抑制剤が開示されている。 Patent Document 2 discloses a polypeptide containing a specific amino acid sequence (23 amino acids), an amide or ester thereof, or a salt thereof, a weight gain inhibitor, a weight loss agent, a fat mass increase agent, and a feeding inhibitor. Agents are disclosed.
一方、近年、腸内細菌のバランスを改善することにより、動物に有益な効果をもたらす生菌添加物が注目されている。これらは、プロバイオティクスと呼ばれ、腸内の有用細菌を増やし、有害物質を作る有害細菌を減らす。体に良いものは残し、体に悪いものは除くという予防医学の観点にたったものであり、体に良いものも悪いものも除いてしまう従来の抗生物質治療剤と異なるものである。例えば、プロバイオティクス食品としては、ヨーグルトが挙げられる。ヨーグルトは牛乳を乳酸菌で発酵させた食品であるが、栄養の機能以外に、乳酸菌による免疫賦活作用、ガン防止効果等のさまざまな効能が知られている。 On the other hand, in recent years, viable bacteria additives that have beneficial effects on animals by improving the balance of enteric bacteria have attracted attention. These are called probiotics, which increase useful bacteria in the gut and reduce harmful bacteria that make harmful substances. It is only from the viewpoint of preventive medicine, leaving good things for the body and excluding things that are bad for the body, and is different from conventional antibiotic treatment agents that remove good things and bad things for the body. For example, yogurt is mentioned as a probiotic food. Yogurt is a food obtained by fermenting milk with lactic acid bacteria. In addition to nutritional functions, yogurt is known to have various effects such as immunostimulatory action and cancer prevention effect by lactic acid bacteria.
酪酸菌（Clostridium butyricum）は、偏性嫌気性の芽胞形成性菌であり、プロバイオティクスとしての酪酸菌が腸内において発育することにより、有機酸並びにビタミンＢ群を産生し、ビフィズス菌・乳酸菌等の腸内の有用細菌の発育を助長し、腐敗や異常発酵の原因になる有害細菌の発育を抑制して腸の働きを正常にすることが知られている。その酪酸菌の培養液、又は当該培養液をろ過して生菌を回収した後に残る酪酸菌培養エキスにも腸内菌叢作用があることが知られている（特許文献３参照）。酪酸菌は、１００℃にも耐えうる胞子を形成し増殖ができない場所、たとえば強酸、強アルカリ、あるいは乾燥条件下にて活動を停止し、環境が良くなると改めて生育を開始することができるため、腸内に生きたまま届くことができる。このような酪酸菌は、長年医薬品または飼料として使われてきており、安全性についても確立されている。
上述したように、さまざまな体重増加抑制剤が開発されているが、これらは体重増加を抑制する効果を有するもののその効果が十分でない場合があった。また、従来の体重増加抑制剤は化学合成品であるため、副作用の面で満足のいかない場合があった。このため、副作用の恐れがなく、安全性に優れた体重増加抑制剤が望まれている。 As described above, various weight gain inhibitors have been developed, but these have the effect of suppressing weight gain, but the effect may not be sufficient. Moreover, since the conventional weight gain inhibitor is a chemically synthesized product, it may not be satisfactory in terms of side effects. For this reason, there is a need for a weight gain inhibitor that is superior in safety and has no fear of side effects.
そこで、本発明は、体重増加を抑制する効果に優れていて、かつ副作用の恐れがなく、安全性に優れた体重増加抑制剤を提供することを目的とする。 Accordingly, an object of the present invention is to provide a weight gain inhibitor that is excellent in the effect of suppressing weight gain, has no fear of side effects, and is excellent in safety.
上記課題を鑑みて鋭意検討した結果、酪酸菌培養液又は酪酸菌培養エキスに関して、体重増加を抑制するという新たな効果を見出した。酪酸菌培養液又は酪酸菌培養エキスは副作用の恐れがなく、安全性に優れていることは従来から知られているため、酪酸菌培養液又は酪酸菌培養エキスは体重増加を抑制する効果に優れていて、かつ副作用の恐れがなく、安全性に優れた体重増加抑制剤となり得ることを見出し、本発明に想到した。 As a result of intensive studies in view of the above problems, the present inventors have found a new effect of suppressing weight gain with respect to a butyric acid culture medium or a butyric acid culture extract. Butyric acid bacteria culture solution or butyric acid bacteria culture extract has no fear of side effects and has been known to be excellent in safety. Butyric acid bacteria culture solution or butyric acid bacteria culture extract is excellent in suppressing body weight gain In addition, the present inventors have found that the present invention can be a weight gain inhibitor that is excellent in safety and has no fear of side effects.
本発明の請求項１の体重増加抑制剤は、酪酸菌（Clostridium butyricum）培養液又は酪酸菌培養エキスを含有することを特徴とする。 The weight gain inhibitor of claim 1 of the present invention is characterized by containing a culture solution of butyric acid bacteria (Clostridium butyricum) or a butyric acid bacteria culture extract.
本発明の請求項２の体重増加抑制剤は、請求項１において、前記酪酸菌（Clostridium butyricum）培養液又は酪酸菌培養エキスに、酪酸菌（Clostridium butyricum）の生体菌及び／又は死菌体を加えることを特徴とする。 The weight gain inhibitor of Claim 2 of the present invention is the body weight increase inhibitor according to Claim 1, wherein the butyric acid bacterium (Clostridium butyricum) culture solution or butyric acid bacterium culture extract is added to the living bacteria and / or dead cells of the butyric acid bacterium (Clostridium butyricum). It is characterized by adding.
本発明の請求項３の体重増加抑制飲料は、酪酸菌（Clostridium butyricum）培養液又は酪酸菌培養エキスを含有することを特徴とする。 The weight gain-suppressing beverage according to claim 3 of the present invention is characterized by containing a culture solution of butyric acid bacteria (Clostridium butyricum) or a butyric acid bacteria culture extract.
本発明の請求項４の体重増加抑制飲料は、請求項３において、前記酪酸菌（Clostridium butyricum）培養液又は酪酸菌培養エキスに、酪酸菌（Clostridium butyricum）の生体菌及び／又は死菌体を加えることを特徴とする。 According to claim 4 of the present invention, there is provided a beverage for suppressing weight gain according to claim 3, wherein the butyric acid bacterium (Clostridium butyricum) culture solution or butyric acid bacterium culture extract is filled with living and / or dead cells of butyric acid bacteria (Clostridium butyricum). It is characterized by adding.
本発明の請求項１によれば、生活習慣病と密接な関係を有する体重増加を抑制するのに有効である。また、プロバイオティクスとしての酪酸菌が、整腸作用、抗菌作用、消化補助等の有益な作用をもたらす。酪酸菌は、有機物を分解してビタミンなどを産生するため、肥満や生活習慣病の一因である栄養の偏りを解消する補助となる。さらに、経口投与による酪酸菌の安全性はすでに確かめられているため、副作用の恐れがない体重増加抑制剤を提供することができる。 According to claim 1 of the present invention, it is effective for suppressing weight gain having a close relationship with lifestyle-related diseases. In addition, butyric acid bacteria as probiotics bring about beneficial effects such as intestinal regulation, antibacterial activity, and digestive aids. Butyric acid bacteria decompose organic substances and produce vitamins and the like, which helps to eliminate the nutritional bias that contributes to obesity and lifestyle-related diseases. Furthermore, since the safety of butyric acid bacteria by oral administration has already been confirmed, it is possible to provide a weight gain inhibitor that is free from side effects.
本発明の請求項２によれば、生活習慣病と密接な関係を有する体重増加を抑制するのにさらに有効である。また、プロバイオティクスとしての酪酸菌が、整腸作用、抗菌作用、消化補助等の有益な作用をもたらす。酪酸菌は、有機物を分解してビタミンなどを産生するため、肥満や生活習慣病の一因である栄養の偏りを解消する補助となる。さらに、経口投与による酪酸菌の安全性はすでに確かめられているため、副作用の恐れがない体重増加抑制剤を提供することができる。 According to claim 2 of the present invention, it is further effective in suppressing weight gain having a close relationship with lifestyle-related diseases. In addition, butyric acid bacteria as probiotics bring about beneficial effects such as intestinal regulation, antibacterial activity, and digestive aids. Butyric acid bacteria decompose organic substances and produce vitamins and the like, which helps to eliminate the nutritional bias that contributes to obesity and lifestyle-related diseases. Furthermore, since the safety of butyric acid bacteria by oral administration has already been confirmed, it is possible to provide a weight gain inhibitor that is free from side effects.
本発明の請求項３によれば、体重増加を抑制する効果に優れていて、かつ副作用の恐れがなく、安全性に優れた酪酸菌（Clostridium butyricum）培養液又は酪酸菌培養エキスを、飲料として手軽に摂取することができる。また、本体重増加抑制飲料はプロバイオティクスとしての酪酸菌の効果が期待できる。 According to claim 3 of the present invention, a butyric acid bacterium (Clostridium butyricum) culture solution or a butyric acid bacterium culture extract that is excellent in the effect of suppressing weight gain, has no fear of side effects, and is excellent in safety is used as a beverage. It can be taken easily. Moreover, this weight gain suppression drink can expect the effect of butyric acid bacteria as probiotics.
本発明の請求項４によれば、体重増加を抑制する効果にさらに優れていて、かつ副作用の恐れがなく、安全性に優れた酪酸菌（Clostridium butyricum）培養液又は酪酸菌培養エキスを、飲料として手軽に摂取することができる。また、本体重増加抑制飲料はプロバイオティクスとしての酪酸菌の効果が期待できる。 According to claim 4 of the present invention, a culture solution or butyric acid bacterium culture extract that is further excellent in the effect of suppressing weight gain, has no fear of side effects, and is excellent in safety is obtained. Can be taken easily. Moreover, this weight gain suppression drink can expect the effect of butyric acid bacteria as probiotics.
以下、本発明の実施形態について詳細に説明する。 Hereinafter, embodiments of the present invention will be described in detail.
本発明に用いられる酪酸菌（Clostridium butyricum）は、偏性嫌気菌で芽胞を形成するグラム陽性の桿菌である。芽胞の形成により、耐熱性、耐酸性をもち、生菌としての安定性に富んでいる。 The butyric acid bacterium (Clostridium butyricum) used in the present invention is a Gram-positive gonococcus that forms spores with obligate anaerobes. Due to the formation of spores, it has heat resistance and acid resistance, and is highly stable as a living microbe.
本発明において酪酸菌培養液とは、酪酸菌を通常の酪酸菌を培養する培地例えば、アミノ酸，バレイショデンプン，水等を含む培地で２０〜４２℃、２０〜７２時間培養して得られる培養液のことをいう。 In the present invention, a butyric acid bacterium culture solution is a culture solution obtained by culturing a butyric acid bacterium in a medium containing normal butyric acid bacteria, for example, a medium containing amino acids, potato starch, water, etc. at 20 to 42 ° C. for 20 to 72 hours. I mean.
また、本発明において酪酸菌培養エキスとは、上記酪酸菌培養液を遠心分離等により固液分離して、得られる液部のことをいう。 Further, in the present invention, the butyric acid bacteria culture extract refers to a liquid part obtained by solid-liquid separation of the above-mentioned butyric acid bacteria culture solution by centrifugation or the like.
なお、酪酸菌培養液又は酪酸菌培養エキス中には、酪酸菌の生菌体及び／又は死菌体の他に、代謝産物である酪酸，酢酸，プロピオン酸等の有機酸、アミラーゼ、各種アミノ酸、ビタミンＢ２、ビタミンＢ６、ビタミンＢ１２、ビタミンＣ、及び自己融解した菌体成分等が含まれている。また、酪酸菌培養液又は酪酸菌培養エキスには有機酸として酪酸や酢酸等を含有しているため、特異臭を有する欠点があるが、この臭いを例えば香料でマスキングしてもよい。香料としては、酪酸菌臭のマスキングに有効なものであれば特に制限されないが、食品添加物として用いられるものが好ましい。 In addition, in the butyric acid bacteria culture solution or butyric acid bacteria culture extract, in addition to live and / or dead cells of butyric acid bacteria, metabolites such as butyric acid, acetic acid, propionic acid and other organic acids, amylase, various amino acids Vitamin B2, Vitamin B6, Vitamin B12, Vitamin C, and self-melting cell components. Moreover, since the butyric acid bacteria culture solution or the butyric acid bacteria culture extract contains butyric acid, acetic acid, or the like as an organic acid, there is a drawback of having a specific odor, but this odor may be masked with a fragrance, for example. The fragrance is not particularly limited as long as it is effective for masking the butyric acid odor, but is preferably used as a food additive.
さらに、上記のようにして得られた酪酸菌培養液又は酪酸菌培養エキスをそのまま用いてもよいが、スプレードライや凍結乾燥などの操作により、エキス粉末として用いることもできる。 Furthermore, the butyric acid bacteria culture solution or butyric acid bacteria culture extract obtained as described above may be used as it is, but can also be used as an extract powder by an operation such as spray drying or freeze drying.
本発明に用いられる酪酸菌の生菌体は、芽胞形成期のものでも栄養体期のものでも制限はないが、ペプチドグリカンを豊富に含有する栄養体期のものが好ましい。栄養体期を豊富に含有する生菌体は、例えばペプトン，イーストエクストラクト，グルコース，水等を含有するＰＹＧ培地などで、２０〜４２℃、２０〜７２時間培養し、遠心分離等の方法で集菌して得ることができる。 The viable cell of butyric acid bacterium used in the present invention is not limited at the spore formation stage or the vegetative stage, but is preferably a vegetative stage containing a large amount of peptidoglycan. Viable cells containing abundant vegetative phase are cultured in a PYG medium containing, for example, peptone, yeast extract, glucose, water, etc., and cultured at 20 to 42 ° C. for 20 to 72 hours, and centrifuged or the like. It can be obtained by collecting bacteria.
また、本発明に用いられる酪酸菌の死菌体は、生菌体を通常の方法により、例えば空気（酸素）被爆や熱処理を用いて処理することによって得られる。死菌体を製造するための生菌としては芽胞形成期のものでも栄養体期のものでも制限はないが、ペプチドグリカンを豊富に含有する栄養体期のものが好ましい。 Moreover, the dead cell of the butyric acid bacterium used for this invention is obtained by processing a living cell by a normal method, for example using air (oxygen) exposure and heat processing. The viable bacteria for producing dead cells are not limited to those in the spore formation stage or in the vegetative stage, but those in the vegetative stage containing a large amount of peptidoglycan are preferable.
本発明の体重増加抑制剤及び体重増加抑制飲料は、酪酸菌培養液又は酪酸菌培養エキスを有効成分として含有するものである。そして、更に酪酸菌培養液又は酪酸菌培養エキスに、酪酸菌の生菌体及び／又は死菌体を１０3個／ｍｌ以上含むことが好ましい。 The weight gain inhibitor and weight gain inhibitor beverage of the present invention contain butyric acid bacteria culture solution or butyric acid bacteria culture extract as an active ingredient. Further, it is preferable that the butyric acid bacteria culture solution or butyric acid bacteria culture extract contains 10 3 / ml or more of butyric acid live cells and / or dead cells.
本発明の体重増加抑制剤を製剤するには、目的、投与形態、投与対象、最終形態等に応じて、上記のようにして得られた酪酸菌培養液又は酪酸菌培養エキス、或いは酪酸菌の生菌体及び／又は死菌体を含有する酪酸菌培養液又は酪酸菌培養エキスに、任意成分として担体、賦形剤、統合剤、安定剤、香料等の添加剤を配合し、例えば錠剤，散剤，顆粒剤，カプセル剤，丸剤，トローチ剤，液剤，エキス剤等の任意の形状に調製することができる。これらは当業者の通常の方法に従って調製することができる。また、本実施形態の体重増加抑制剤は、そのまま単独で或いは一部分にそれを含ませたものとして配合してもよい。 In order to formulate the weight gain inhibitor of the present invention, depending on the purpose, administration form, administration target, final form, etc., butyric acid bacteria culture solution or butyric acid bacteria culture extract obtained as described above, or butyric acid bacteria A butyric acid bacterium culture solution or a butyric acid bacterium culture extract containing live cells and / or dead cells is blended with additives such as carriers, excipients, integrating agents, stabilizers, fragrances, etc. as optional components, for example, tablets, Powders, granules, capsules, pills, troches, liquids, extracts and the like can be prepared. These can be prepared according to the usual methods of one skilled in the art. Moreover, you may mix | blend the weight increase inhibitor of this embodiment as it is, or what included it in one part as it is.
また、上記の酪酸菌培養液又は酪酸菌培養エキス、或いは酪酸菌の生菌体及び／又は死菌体を含有する酪酸菌培養液又は酪酸菌培養エキスを飲料に加えて、一般の製造法により、本発明の体重増加抑制飲料を加工製造することができる。飲料としては、炭酸飲料，清涼飲料，乳飲料，コーヒー飲料，ミネラルウォーター，アルコール飲料，果汁飲料，茶類，栄養飲料等が挙げられる。また、上記の酪酸菌培養液又は酪酸菌培養エキス、或いは酪酸菌の生菌体及び／又は死菌体を含有する酪酸菌培養液又は酪酸菌培養エキスを上記飲料以外の飲食物に加え、一般の製造法により、あめ、せんべい、クッキー、調味料、米穀類、パン、麺類等の飲食物を加工製造することができる。なお、本発明における体重増加抑制剤中には１０3個／ｍｌ以上の酪酸菌培養液の生菌体及び／又は死菌体が含まれているのが好ましい。 In addition, the above-mentioned butyric acid bacteria culture solution or butyric acid bacteria culture extract, or butyric acid bacteria culture solution or butyric acid bacteria culture extract containing live and / or dead cells of butyric acid bacteria is added to the beverage, The weight gain-suppressing beverage of the present invention can be processed and manufactured. Examples of drinks include carbonated drinks, soft drinks, milk drinks, coffee drinks, mineral water, alcoholic drinks, fruit juice drinks, teas, and nutritional drinks. In addition, the above-mentioned butyric acid bacteria culture solution or butyric acid bacteria culture extract, butyric acid bacteria culture solution or butyric acid bacteria culture extract containing live cells and / or dead cells of butyric acid bacteria are added to foods and drinks other than the above beverages, According to this production method, foods and drinks such as candy, rice crackers, cookies, seasonings, rice grains, bread, and noodles can be processed and produced. In addition, it is preferable that the body weight increase inhibitor in the present invention contains 10 3 cells / ml or more butyric bacteria and / or dead cells.
本発明の体重増加抑制剤及び体重抑制飲料は、美容のための使用に限定されず、糖尿病、高血圧症及び高脂血症などの生活習慣病の発生の予防並びに糖尿病、高血圧症及び高脂血症などの生活習慣病の治療の補助のために使用することができる。 The weight gain inhibitor and weight-suppressing beverage of the present invention are not limited to use for beauty, but prevent the occurrence of lifestyle-related diseases such as diabetes, hypertension and hyperlipidemia, and diabetes, hypertension and hyperlipidemia. Can be used to assist in the treatment of lifestyle-related diseases such as illness.
以下、本発明の調製例、実験例及び実施例を挙げて本発明を詳細に説明するが、本発明は下記の例に限定されるものではない。 Hereinafter, the present invention will be described in detail with reference to preparation examples, experimental examples and examples of the present invention, but the present invention is not limited to the following examples.
〔製造例〕酪酸菌培養エキスの製造方法例：酪酸菌（Clostridium butyricum)を、バレイショ培地〔（バレイショデンプン１．０重量％，アミノ酸１．０重量％，水９８．０重量％）又は（バレイショデンプン０．５重量％，アミノ酸０．５重量％，食塩０．１重量％，水９８．９重量％）〕で、２０〜４２℃、２０〜７２時間培養し、遠心分離により固液分離を行い、この液部を酪酸菌培養エキス１として使用した。 [Production example] Production method example of butyric acid bacterium culture extract: Butyric acid bacterium (Clostridium butyricum) was added to potato medium [(potato starch 1.0% by weight, amino acid 1.0% by weight, water 98.0% by weight) or (potato Starch 0.5% by weight, amino acid 0.5% by weight, sodium chloride 0.1% by weight, water 98.9% by weight)] and cultured at 20-42 ° C. for 20-72 hours, followed by solid-liquid separation by centrifugation. This liquid part was used as butyric acid bacteria culture extract 1.
酪酸菌の栄養体死菌体の分取方法例：酪酸菌（Clostridium butyricum）を、グルコース培地（ブドウ糖１．０重量％，アミノ酸１．０重量％，水９８．０重量％）で、２０〜４２℃、２０〜７２時間培養した。次いで、遠心分離により、固液分離を行い、液部と菌体等を含む固相部に分離し、菌体を回収した。この菌体を、オートクレーブにて１００℃以上で１５分間以上滅菌し、栄養体死菌体を得た。 Example of a method for separating vegetative dead cells of a butyric acid bacterium: Clostridium butyricum in a glucose medium (glucose 1.0 wt%, amino acid 1.0 wt%, water 98.0 wt%) The cells were cultured at 42 ° C. for 20 to 72 hours. Next, solid-liquid separation was performed by centrifugation, and the solid was separated into a solid part containing a liquid part and bacterial cells, and the bacterial cells were collected. The cells were sterilized in an autoclave at 100 ° C. or higher for 15 minutes or more to obtain dead vegetative cells.
また、上記酪酸菌培養エキス１に、上述のようにして得られた栄養体死菌体を１０3個／ｍｌ以上添加し、これを酪酸菌培養エキス２とした。
〔試験方法〕ＮＣ／Ｎｇａ ＴｎｄＣｒｊ系雄性３５日齢マウス（日本チャールズリバー株式会社）のうち、健康と判断したマウスを実験に使用した。１群６匹として、体重が均一になるようにこれらのマウスを２群に分けた。エキス群には、マウス用基本飼料及び酪酸菌培養エキス２をマウスに与え、時間経過によるその体重の推移を調べた。対照として水道水群には酪酸菌培養エキス２の代わりに水道水とマウス用基本飼料を与え、時間経過によるその体重の推移を調べた。なお、マウス用基本飼料として精製飼料（AIN９３G，オリエンタル酵母株式会社製）を使用した。
Further, 10 3 cells / ml or more of the vegetative dead cells obtained as described above were added to the above-mentioned butyric acid bacteria culture extract 1 to obtain butyric acid bacteria culture extract 2.
[Test Method] Among the NC / Nga TndCrj male 35 day old mice (Nippon Charles River Co., Ltd.), mice judged to be healthy were used in the experiment. These mice were divided into 2 groups so that the body weight was uniform as 6 animals per group. In the extract group, mice were given basic feed for mice and butyric acid bacteria culture extract 2 and the changes in body weight over time were examined. As a control, tap water and basic feed for mice were given to the tap water group instead of butyric acid bacteria culture extract 2, and the change in body weight over time was examined. In addition, refined feed (AIN93G, manufactured by Oriental Yeast Co., Ltd.) was used as a basic feed for mice.
図１は体重の推移を表した図面である。図１に示すように、同一の飼料を摂取しているにもかかわらず、エキス群は、水道水群に比べ、体重は少なかった。このことより、酪酸菌培養エキス２には体重増加抑制作用があることが明らかとなった。 FIG. 1 is a drawing showing changes in body weight. As shown in FIG. 1, although the same feed was ingested, the extract group had less weight than the tap water group. From this, it became clear that the butyric acid bacteria culture extract 2 has a body weight gain inhibitory effect.
本発明の体重増加抑制剤の例を示す。実施例１の製造例で得た酪酸菌培養エキス２を、真空下で遠赤外線を照射して加熱して乾燥した。加熱温度は２８〜４０℃である。その後、乾燥物を砕機で粉砕し、酪酸菌末１５０ｍｇを精製でんぷん末１５０ｍｇ及び乳糖７００ｍｇと混合して錠剤を得た。 The example of the weight gain inhibitor of this invention is shown. The butyric acid bacteria culture extract 2 obtained in the production example of Example 1 was dried by irradiation with far-infrared rays under vacuum. The heating temperature is 28-40 ° C. Thereafter, the dried product was pulverized with a crusher, and 150 mg of butyric acid powder was mixed with 150 mg of purified starch powder and 700 mg of lactose to obtain tablets.
本発明の体重増加抑制飲料の例を示す。実施例１の製造例で得た酪酸菌培養エキス２を、ポンプにて加圧スプレーにより、１５０〜１８０℃で熱風で瞬間乾燥した。更に、６０〜８５℃で二次乾燥して、乾燥物を砕機で粉砕し、酪酸菌末を得た。この酪酸菌末０．１ｇをリンゴ果汁１００％のジュース１リットルに添加・混合して、ジュースを得た。 The example of the weight gain suppression drink of this invention is shown. The butyric acid bacteria culture extract 2 obtained in the production example of Example 1 was instantaneously dried with hot air at 150 to 180 ° C. by pressure spraying with a pump. Furthermore, secondary drying was performed at 60 to 85 ° C., and the dried product was pulverized with a crusher to obtain a butyric acid powder. 0.1 g of this butyric acid powder was added to and mixed with 1 liter of 100% apple juice to obtain a juice.
Claims (4)
4. The body weight gain-suppressing beverage according to claim 3, wherein living and / or dead cells of butyric acid bacteria (Clostridium butyricum) are added to the culture solution or butyric acid bacteria culture extract of said butyric acid bacteria (Clostridium butyricum).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005212821A JP2007031291A (en) | 2005-07-22 | 2005-07-22 | Body weight increase-inhibiting agent and body weight increase-inhibiting drink |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005212821A JP2007031291A (en) | 2005-07-22 | 2005-07-22 | Body weight increase-inhibiting agent and body weight increase-inhibiting drink |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2007031291A true JP2007031291A (en) | 2007-02-08 |
Family
ID=37790973
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005212821A Pending JP2007031291A (en) | 2005-07-22 | 2005-07-22 | Body weight increase-inhibiting agent and body weight increase-inhibiting drink |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2007031291A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012011174A1 (en) * | 2010-07-22 | 2012-01-26 | ビオフェルミン製薬株式会社 | Lipid metabolism improving agent, agent for enhancing lipid metabolism improving action, anti-obesity agent, and agent for enhancing anti-obesity action |
| JP2017535597A (en) * | 2014-10-31 | 2017-11-30 | ホール バイオーム インコーポレイテッド | Methods and compositions for microbial treatment and diagnosis of disorders |
| US11583558B2 (en) | 2017-08-30 | 2023-02-21 | Pendulum Therapeutics, Inc. | Methods and compositions for treatment of microbiome-associated disorders |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0692862A (en) * | 1992-01-23 | 1994-04-05 | Osamu Otani | Improver for intestinal flora |
-
2005
- 2005-07-22 JP JP2005212821A patent/JP2007031291A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0692862A (en) * | 1992-01-23 | 1994-04-05 | Osamu Otani | Improver for intestinal flora |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012011174A1 (en) * | 2010-07-22 | 2012-01-26 | ビオフェルミン製薬株式会社 | Lipid metabolism improving agent, agent for enhancing lipid metabolism improving action, anti-obesity agent, and agent for enhancing anti-obesity action |
| JP2017535597A (en) * | 2014-10-31 | 2017-11-30 | ホール バイオーム インコーポレイテッド | Methods and compositions for microbial treatment and diagnosis of disorders |
| US10668116B2 (en) | 2014-10-31 | 2020-06-02 | Pendulum Therapeutics, Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| US10675312B2 (en) | 2014-10-31 | 2020-06-09 | Pendulum Therapeutics, Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| US10842831B2 (en) | 2014-10-31 | 2020-11-24 | Pendulum Therapeutics, Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| US10842830B2 (en) | 2014-10-31 | 2020-11-24 | Pendulum Therapeutics, Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| EP3881680A1 (en) * | 2014-10-31 | 2021-09-22 | Pendulum Therapeutics, Inc. | Methods and compositions relating to microbial treatment |
| US11213556B2 (en) | 2014-10-31 | 2022-01-04 | Pendulum Therapeutics, Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| US11278580B2 (en) | 2014-10-31 | 2022-03-22 | Pendulum Therapeutics, Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| US11364270B2 (en) | 2014-10-31 | 2022-06-21 | Pendulum Therapeutics, Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| US11931387B2 (en) | 2014-10-31 | 2024-03-19 | Pendulum Therapeutics, Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| US11583558B2 (en) | 2017-08-30 | 2023-02-21 | Pendulum Therapeutics, Inc. | Methods and compositions for treatment of microbiome-associated disorders |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6684966B2 (en) | Novel Lactobacillus sakei and composition containing the same | |
| KR101492650B1 (en) | Agent for accelerating the increase in and/or preventing the decrease in blood adiponectin level, and visceral fat accumulation inhibitor | |
| KR102153080B1 (en) | A novel strain of Lactobacillus salivarius HEM 1047, and composition for improving gut environment comprising the strain or its culture fluid | |
| EP3725321A1 (en) | Composition containing bacterium belonging to genus bifidobacterium as active ingredient | |
| EP3981255A1 (en) | Nutritional composition | |
| KR102174095B1 (en) | A novel strain of Enterococcus faecium HEM 200, and composition for improving gut environment comprising the strain or its culture fluid | |
| JPWO2012063826A1 (en) | Lactobacillus helveticus having high proteolytic activity | |
| CN107530387B (en) | Oral composition containing Bifidobacterium and cruciferous vegetable | |
| KR102201517B1 (en) | A novel strain of Lactobacillus acidophilus HEM 960, and composition for improving gut environment comprising the strain or its culture fluid | |
| KR20100119875A (en) | Agents for promoting secretion and/or suppressing decrease of adiponectin | |
| JP5229977B2 (en) | Blood adiponectin concentration increase promoting and / or decreasing inhibitor | |
| JP2007082403A (en) | Food and drink containing complex composition comprising yucca extract, quillaia extract and lactobacillus, and method for producing the same | |
| JP2007031291A (en) | Body weight increase-inhibiting agent and body weight increase-inhibiting drink | |
| JP5089942B2 (en) | Visceral fat accumulation inhibitor | |
| JP5113057B2 (en) | Lipid metabolism improver | |
| JP2007126399A (en) | Composition for increasing glutathione | |
| WO2019188943A1 (en) | Composition for preventing and/or ameliorating decrease in brain blood flow | |
| JP5836928B2 (en) | Inhibitor of increase and decrease of bifidobacteria in the large intestine | |
| KR102215592B1 (en) | A novel strain of Lactobacillus fermentum HEM 1036, and composition for improving gut environment comprising the strain or its culture fluid | |
| KR102215596B1 (en) | A novel strain of Streptococcus thermophilus HEM 14, and composition for improving gut environment comprising the strain or its culture fluid | |
| WO2021059894A1 (en) | Composition, food/beverage composition that contains said composition, and modified milk | |
| WO2020116511A1 (en) | Composition for suppressing norovirus infection | |
| Cruz Casas et al. | Probiotics as functional foods | |
| JP2006143677A (en) | Anti-allergic material | |
| JP6671950B2 (en) | Functional gastrointestinal amelioration agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070315 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100628 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20101025 |